Tiny study probes key player in blood vessel health
NCT ID NCT02086253
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed study looked at how a natural chemical called endothelin-1 affects the widening of arteries in response to increased blood flow. Eight healthy young men received drugs that block specific receptors for endothelin-1 to see how their arteries reacted. The goal was to better understand blood vessel function, which could help explain problems in conditions like high blood pressure.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- BQ-788 and/or BQ-123
- What this could lead to
- If successful, this could help explain why blood vessels don't widen properly in conditions like high blood pressure, pointing toward new treatment targets.
- What could go wrong
- This is a very small, early study in only 8 healthy young men, so results may not apply to older or sicker people. It is designed to gather knowledge, not test a treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
8 people
The number who actually took part.
- Start date
-
Feb 2014
- Finished
-
May 2014
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 35 years
- Sex
-
Male participants only
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Male, Caucasian, aged 18 to 35 years * Non-Smoking * Resting heart rate\> 50 and \<90 bpm * SBP \<140 mmHg and DBP \<90 mm Hg at rest in the supine position for 10 minutes * Normal ECG Exclusion Criteria: * Known allergy * Intolerance to glyceryl trinitrate * Intolerance to lidocaine * Family history of hypertension * Excessive alcohol consumption ( more than 50 g / day) * Addiction or presumption of illicit drug use * Subject refusing blood samples for serology of hepatitis B , C and HIV * History of illness or psychological or sensory abnormality that may prevent the subject to understand the requirements for participation in the protocol or prevents giving informed consent * Metabolic or endocrine disease * Immunological diseases * Renal or hepatic impairment * Ischemic or obstructive heart disease * Neoplastic disease * Gastrointestinal disease * Neurological disease , intracranial hypertension , seizure disorders * Compulsive overeating , bulimia, anorexia * Severe psychiatric illness * Presence of a clinically significant abnormality in laboratory tests carried out at the inclusion visit . * HBs Ag , HCV Ab , Ac HIV 1 or HIV 2 positive . * The use of any drug in the range of less than 5 half-life time, in particular betablockers, sildenafil, cimetidine, amiodarone .
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Healthy conditions are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHU - Hôpitaux de Rouen
Rouen, Normandy, 76031, France